4.5 Article

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

期刊

EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
卷 2021, 期 12, 页码 1924-1930

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/ejoc.202100058

关键词

API synthesis; Asymmetric synthesis; Green chemistry; Homogenous catalysis

向作者/读者索取更多资源

A short enantioselective synthesis of Ozanimod was reported, with the stereogenic center introduced through imine asymmetric transfer hydrogenation, resulting in high enantioselectivity. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in only 5 steps with a high overall yield of 62% and 99% ee.
We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1P(R)), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills' catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据